MDMahmoud Dehghani-Ghorbi

Mahmoud Dehghani-Ghorbi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Mahmoud Dehghani-Ghorbi has a total of 25 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    A new era in melanoma immunotherapy: focus on DCs metabolic reprogramming

    by Mina Afrashteh Nour, Mansour Rajabivahid, Marjan Sadat Seyed Mehdi, Safa Tahmasebi, Sepideh Nasirzadeh Dashtgol, Mahmoud Dehghani-Ghorbi, Ahmad Ghorbani Vanan, Farid Ghorbaninezhad

    Melanoma, being one of the most dangerous forms of skin cancer, is characterized by its aggressive and metastatic nature, with the potential to develop resistance to various treatments. This resistance makes the disease challenging to treat, emphasizing the need for new treatment strategies. Within the tumor microenvironment (TME), melanoma cells exploit metabolic shifts, particularly glycolysis, to create an immunosuppressive TME that prevents dendritic cells (DCs) from functioning properly. Essential metabolic alterations such as lactate and lipid accumulation, and lack of tryptophan disrupt DC maturation, antigen presentation, and T cell activation. In recent years, melanoma immunotherapy has increasingly focused on reprogramming the metabolism of DCs. This review paper aims to provide insights into the metabolic suppression of melanoma-associated DCs, allowing the design of therapeutic strategies based on metabolic interventions to promote or restore DC function. This contribution reviews the metabolic reprogramming of DCs as a new approach for melanoma immunotherapy.


  • Open Access

    Long non-coding RNAs (lncRNAs) in cancer development: new insight from STAT3 signaling pathway to immune evasion

    by Lie Ma, XuQing Liu, R Roopashree, Syeda Wajida Kazmi, Saade Abdalkareem Jasim, K. Phaninder Vinay, Ata Fateh, Fang Yang, Mansour Rajabivahid, Mahmoud Dehghani-Ghorbi, et al.

    Overcoming cancer and enhancing patient survival are becoming increasingly challenging due to the uncontrolled growth and metastasis of colorectal cancer cells. In order to provide effective cancer treatment and minimize the malignancy of cancer cells, it is necessary to understand how complex signaling networks contribute to their invasion and proliferation. The signal transducer and activator of transcription 3 (STAT3) is a promising target due to its involvement in various cellular functions, including apoptosis, immunosuppression, cell invasion, migration, and proliferation. Dysregulation of STAT3 signaling is associated with diseases, particularly colorectal cancer. Long non-coding RNAs (lncRNAs), a subset of non-coding RNAs, are essential for the progression, apoptosis, and metastasis of CRC as they regulate key signaling pathways such as STAT3 signaling and contribute to gene regulation at the epigenetic, transcriptional, and post-transcriptional levels. Moreover, lncRNAs have a key function in regulating immune cells function through STAT3. In this study, we comprehensively reviewed the regulatory roles of different lncRNAs on STAT3 and the mutual effects of this pathway in various aspects of carcinogenesis, including proliferation, apoptosis, metastasis, drug resistance, and angiogenesis. Moreover, we investigate the effects of lncRNA/STAT3 axis on the function of different immune cells that play critical role in the tumor microenvironment.


  • LncRNAs involvement in pathogenesis of immune-related disease via regulation of T regulatory cells, an updated review

    by Shayan Khalilollah, Sina Kalantari Soltanieh, Raed Obaid Saleh, Abdullah Ali Alzahrani, Hatem Ghaleb Maabreh, Mais Mazin Al-Hamdani, Mahmoud Dehghani-Ghorbi, Metanat Shafiei Khonachaei, Reza Akhavan-Sigari